{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-000348","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.001711+00:00","generated_at":"2026-06-27T20:35:51.702750+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Trevi announces interim analysis for Phase 2 CANAL trial in Q1 2022, ends PRISM enrollment Jan 31","bullets":["Phase 2 CANAL trial of Haduvio for chronic cough in IPF: interim statistical update planned Q1 2022 based on conditional power.","Top-line data from CANAL expected H1 2022; interim may allow proof-of-concept before full enrollment.","Phase 2b/3 PRISM trial for prurigo nodularis: enrollment ends Jan 31, 2022; top-line data H1 2022.","Top-line data from both trials expected in first half of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-000348","json":"https://secwatch.observer/filing/0001564590-22-000348.json","markdown":"https://secwatch.observer/filing/0001564590-22-000348.md","text":"https://secwatch.observer/filing/0001564590-22-000348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022000348/0001564590-22-000348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022000348/trvi-8k_20220105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:35:51.702750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}